Sarcoma

Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children

Retrieved on: 
Friday, March 1, 2024

Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.

Key Points: 
  • Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.
  • (Photo: Business Wire)
    When cancer reoccurs in children and young adults with solid tumors such as sarcomas and neuroblastomas, there are few good treatment options.
  • This is why Children’s Hospital Los Angeles researchers focus on finding novel therapies using the patient’s own immune cells to treat childhood cancers.
  • In 2022, CIRM awarded $8 million to the Keck School of Medicine of USC and Children’s Hospital Los Angeles to establish a CIRM Alpha Clinic.

OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, February 15, 2024

BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H.

Key Points: 
  • BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H.
  • as Chief Medical Officer.
  • “Sam’s leadership experience and expertise in oncology drug development will be invaluable as we advance our portfolio,” said Nick Saccomano, Ph.D., Chief Executive Officer of OnKure.
  • Dr. Agresta also served as a Director and Chief Medical Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the Phase 1 and 2 developments of the PI3Ky inhibitor, IPI-549.

Prostate Cancer Prevention and Treatment Technologies: Comprehensive Global Market Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global market for prostate cancer care reached $35.3 billion in 2022.
  • The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028.
  • Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs.

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Retrieved on: 
Monday, February 12, 2024

MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB

Key Points: 
  • MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB
    Planegg/Martinsried, February 12, 2024.
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the selection of gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma, as the initial clinical indications for its lead candidate MDG1015.
  • Preclinical data presented in 2023 at the AACR and ESMO conferences demonstrated the clear potential of MDG1015 to improve clinical outcomes in solid tumors.
  • “The selection of these cancers as targets for MDG1015 is an important step as we advance towards the first-in-human trial.

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Retrieved on: 
Wednesday, February 7, 2024

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).

Key Points: 
  • MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
  • QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
  • Telix believes that 153Sm-DOTMP may benefit patients with metastatic lung and breast cancer, where many patients develop brain and bone metastases, and disease management often focusses on quality-of-life palliative care.
  • Telix will issue ordinary shares to the stockholders of QSAM at closing within its Listing Rule 7.1 placement capacity as consideration for the acquisition.

Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001

Retrieved on: 
Tuesday, February 6, 2024

Munich, Germany – February 6, 2024 – Thermosome , a drug development company specializing in targeted tumor therapies, today announced that it received clearance by the independent Data Safety Monitoring Board (DSMB) to proceed as planned with the dose escalation in its ongoing Phase I trial of its lead program THE001.

Key Points: 
  • Munich, Germany – February 6, 2024 – Thermosome , a drug development company specializing in targeted tumor therapies, today announced that it received clearance by the independent Data Safety Monitoring Board (DSMB) to proceed as planned with the dose escalation in its ongoing Phase I trial of its lead program THE001.
  • The first dose level was 20mg/m2, the second, recently initiated dose level is 40mg/m2.
  • Primary endpoints of the study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose.
  • "The independent Data Safety Monitoring Board has assessed that our lead candidate is safe and well tolerated at the first dose level.

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq

Retrieved on: 
Tuesday, January 23, 2024

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq

Key Points: 
  • HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq
    1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost to the clinic.
  • HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer, today announced that it has raised a €2 million seed round to finance GMP transfer and advance its lead candidate towards the clinic.
  • The round was co-led by xista science ventures and the Foundation Fournier-Majoie, with the participation of Noshaq.
  • « The Foundation is very pleased to be part of HEPHAISTOS-Pharma thanks to this financing round.

RenovoRx Closes $6.1 Million Private Placement

Retrieved on: 
Monday, January 29, 2024

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.

Key Points: 
  • RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.
  • RenovoRx insiders, including members of the management team and Board of Directors, participated in the private placement.
  • The warrants are exercisable at a price equal to the per share price paid by the applicable investor and are exercisable for a period of five years following the closing of the private placement.
  • “I have now chosen to join as an investor in this private placement financing.

Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery

Retrieved on: 
Sunday, January 28, 2024

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024).

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024).
  • The data demonstrate that VGT-309, the company’s investigational tumor-targeted fluorescent imaging agent, visualizes primary and metastatic tumor tissue in the lung during surgery.
  • The findings reinforce results from earlier clinical trials of VGT-309 which suggest the agent may help surgeons see difficult-to-find and previously undetected tumors in real time, ensuring all tumor tissue is removed during minimally invasive (MIS) and robotic-assisted lung cancer surgery.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress Its Proprietary CCR8 Antibody Candidate to the Clinic

Retrieved on: 
Thursday, January 25, 2024

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.
  • View the full release here: https://www.businesswire.com/news/home/20240125583037/en/
    The SPRINT project aims to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care.
  • The grant that we have been awarded by the RHU SPRINT consortium will support the progress of DT-7012, an anti-CCR8 monoclonal antibody which has incredible potential as a best-in-class therapeutic, into the clinic.
  • Domain was already awarded a first RHU grant, RHU CONDOR for Sarcoma, in the previous campaign, leveraging another proprietary asset.